Laura Gianolio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Laura Gianolio has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
- Gianvincenzo Zuccotti
Department of Pediatrics Vittore Buzzi Children's Hospital Milan Italy
9 shared publications - Richard Kay Russell
NHS Scotland, Edinburgh, UK
6 shared publications - David C. Wilson
Child Life and Health, Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK
4 shared publications - Lorenzo Norsa
Department of Paediatrics, Vittore Buzzi Children's Hospital, University of Milan, Milan, Italy
4 shared publications - Valeria Calcaterra
Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy
4 shared publications - Marina Aloi
Department of Pathophysiology and Transplantation University of Milan Milan Italy
3 shared publications
Latest Publications
- 10 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Low‐risk paediatric Crohn's disease: A narrative review of current evidence and unmet research needs
While current paediatric management increasingly favours early intensive treatment for children and adolescents with Crohn's disease (CD) at high risk of disease progression, a smaller subset of patients presents with a potentially ‘low‐risk’ disease phenotype. Identifying these children is clinically challenging, as overtreatment may expose them to unnecessary risks and costs, whereas undertreatment may allow irreversible bowel damage and complications to develop. This narrative review summarises the current evidence on the definition, assessment, treatment, and monitoring of low‐risk paediatric CD, highlighting existing knowledge gaps and future research priorities. At present, no consensus definition of low‐risk paediatric CD exists, and disease classification relies largely on the absence of recognised high‐risk features rather than validated criteria. Similarly, unlike adult practice, no paediatric prognostic model is available to identify children likely to follow a persistently mild disease course. Current assessment requires integration of clinical indices, inflammatory biomarkers, endoscopy, cross‐sectional imaging, and evaluation of growth and nutritional status. Dietary treatment (Exclusive Enteral Nutrition and emerging dietary strategies, including the CD Exclusion Diet [CDED] and the Tasty & Healthy [T&H]] remains the commonest induction therapy. Budesonide or antibiotics (azithromycin and metronidazole) represent an appropriate alternative for selected children. CDED and the T&H diet may also represent attractive medium term treatment options, although robust maintenance data are still awaited. Prospective studies are needed to establish a consensus definition, develop paediatric‐specific prediction models, optimise risk stratification, and determine the most effective long‐term therapeutic and monitoring approaches for the ‘low‐risk’ population.
- 10 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Low‐risk paediatric Crohn's disease: A narrative review of current evidence and unmet research needs
While current paediatric management increasingly favours early intensive treatment for children and adolescents with Crohn's disease (CD) at high risk of disease progression, a smaller subset of patients presents with a potentially ‘low‐risk’ disease phenotype. Identifying these children is clinically challenging, as overtreatment may expose them to unnecessary risks and costs, whereas undertreatment may allow irreversible bowel damage and complications to develop. This narrative review summarises the current evidence on the definition, assessment, treatment, and monitoring of low‐risk paediatric CD, highlighting existing knowledge gaps and future research priorities. At present, no consensus definition of low‐risk paediatric CD exists, and disease classification relies largely on the absence of recognised high‐risk features rather than validated criteria. Similarly, unlike adult practice, no paediatric prognostic model is available to identify children likely to follow a persistently mild disease course. Current assessment requires integration of clinical indices, inflammatory biomarkers, endoscopy, cross‐sectional imaging, and evaluation of growth and nutritional status. Dietary treatment (Exclusive Enteral Nutrition and emerging dietary strategies, including the CD Exclusion Diet [CDED] and the Tasty & Healthy [T&H]] remains the commonest induction therapy. Budesonide or antibiotics (azithromycin and metronidazole) represent an appropriate alternative for selected children. CDED and the T&H diet may also represent attractive medium term treatment options, although robust maintenance data are still awaited. Prospective studies are needed to establish a consensus definition, develop paediatric‐specific prediction models, optimise risk stratification, and determine the most effective long‐term therapeutic and monitoring approaches for the ‘low‐risk’ population.
- 17 September 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Current practices and unmet needs in the management of Clostridioides difficile infection in pediatric inflammatory bowel disease: A national survey
Objectives: Children with inflammatory bowel disease (IBD) are at increased risk for Clostridioides difficile infection (CDI), which is associated with worse clinical outcomes. We aimed to assess current diagnostic and therapeutic practices for CDI among Italian pediatric IBD centers. Methods: A nationwide survey was conducted in 2025 using a structured 28‐item questionnaire distributed to all pediatric IBD centers in Italy. Items addressed diagnostic strategies, treatment approaches, recurrence management, and immunosuppressive therapy handling in children with IBD and CDI. Results: Twenty‐seven centers responded (response rate, 90%). Diagnostic approaches varied: toxin enzyme immunoassays (EIA) were indicated by 21/27 centers (78%), glutamate dehydrogenase (GDH) testing by 19/27 (70%), and nucleic acid amplification tests (NAAT) by 13/27 (48%). Routine CDI testing at IBD diagnosis was indicated by 12/27 centers (44%), whereas 23/27 (85%) reported testing during IBD flares. For a first non‐severe episode, vancomycin and metronidazole were equally identified as preferred first‐line options (18/27; 66% each). Oral vancomycin was the preferred treatment for recurrent CDI (26/27; 96%). Third or subsequent recurrences prompted consideration of fidaxomicin (19/27; 70%), fecal microbiota transplantation (6/27; 22%), and bezlotoxumab (2/27; 7%). In fulminant CDI, 7/27 centers (26%) indicated adding fidaxomicin to standard therapy. In acute severe colitis with concomitant CDI at diagnosis, 18/27 centers (67%) described a cautious approach to biologic initiation. Conclusions: This nationwide survey highlights substantial unmet needs in CDI management in pediatric IBD, including variability in diagnostic strategies, lack of consensus on first‐line therapy, and uncertainty regarding immunosuppressive management, supporting the need for evidence‐based pediatric‐specific guidelines.
- 17 September 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Current practices and unmet needs in the management of Clostridioides difficile infection in pediatric inflammatory bowel disease: A national survey
Objectives: Children with inflammatory bowel disease (IBD) are at increased risk for Clostridioides difficile infection (CDI), which is associated with worse clinical outcomes. We aimed to assess current diagnostic and therapeutic practices for CDI among Italian pediatric IBD centers. Methods: A nationwide survey was conducted in 2025 using a structured 28‐item questionnaire distributed to all pediatric IBD centers in Italy. Items addressed diagnostic strategies, treatment approaches, recurrence management, and immunosuppressive therapy handling in children with IBD and CDI. Results: Twenty‐seven centers responded (response rate, 90%). Diagnostic approaches varied: toxin enzyme immunoassays (EIA) were indicated by 21/27 centers (78%), glutamate dehydrogenase (GDH) testing by 19/27 (70%), and nucleic acid amplification tests (NAAT) by 13/27 (48%). Routine CDI testing at IBD diagnosis was indicated by 12/27 centers (44%), whereas 23/27 (85%) reported testing during IBD flares. For a first non‐severe episode, vancomycin and metronidazole were equally identified as preferred first‐line options (18/27; 66% each). Oral vancomycin was the preferred treatment for recurrent CDI (26/27; 96%). Third or subsequent recurrences prompted consideration of fidaxomicin (19/27; 70%), fecal microbiota transplantation (6/27; 22%), and bezlotoxumab (2/27; 7%). In fulminant CDI, 7/27 centers (26%) indicated adding fidaxomicin to standard therapy. In acute severe colitis with concomitant CDI at diagnosis, 18/27 centers (67%) described a cautious approach to biologic initiation. Conclusions: This nationwide survey highlights substantial unmet needs in CDI management in pediatric IBD, including variability in diagnostic strategies, lack of consensus on first‐line therapy, and uncertainty regarding immunosuppressive management, supporting the need for evidence‐based pediatric‐specific guidelines.
- Open Access
How Long Should We Taper Corticosteroids in Ulcerative Colitis? Insights From a Randomised Controlled Trial
Despite the widespread adoption of steroid‐sparing strategies, corticosteroids remain a cornerstone of induction therapy for moderate‐to‐severe ulcerative colitis (UC), yet the optimal tapering strategy remains poorly defined. This Y‐ECCO literature review summarises the randomised controlled trial by Kumar et al., which investigated the impact of steroid tapering duration in steroid‐responsive moderate‐to‐severe UC. In this prospective, single‐centre, double‐blind, non‐inferiority study, patients responding after 2 weeks of induction steroid therapy were randomised to a 10‐week (long) or 6‐week (short) prednisolone taper, with placebo matching preserving blinding over a total treatment duration of 10 weeks in both arms. Patients received 5‐aminosalicylates and, in most cases, thiopurines as concomitant maintenance therapy. The 10‐week taper was associated with higher steroid‐free remission rates at 6 months and a longer time to relapse, while relapse rates, endoscopic healing, histological remission and safety were comparable between groups. Although these findings suggest that a longer taper may be advantageous in patients receiving conventional maintenance therapy, several methodological limitations temper their interpretation. Nevertheless, this study provides valuable randomised evidence in an area still largely guided by expert opinion and highlights the need for adequately powered trials that tailor steroid tapering to the maintenance strategy while minimising cumulative corticosteroid exposure.
Open AccessHow Long Should We Taper Corticosteroids in Ulcerative Colitis? Insights From a Randomised Controlled Trial
Despite the widespread adoption of steroid‐sparing strategies, corticosteroids remain a cornerstone of induction therapy for moderate‐to‐severe ulcerative colitis (UC), yet the optimal tapering strategy remains poorly defined. This Y‐ECCO literature review summarises the randomised controlled trial by Kumar et al., which investigated the impact of steroid tapering duration in steroid‐responsive moderate‐to‐severe UC. In this prospective, single‐centre, double‐blind, non‐inferiority study, patients responding after 2 weeks of induction steroid therapy were randomised to a 10‐week (long) or 6‐week (short) prednisolone taper, with placebo matching preserving blinding over a total treatment duration of 10 weeks in both arms. Patients received 5‐aminosalicylates and, in most cases, thiopurines as concomitant maintenance therapy. The 10‐week taper was associated with higher steroid‐free remission rates at 6 months and a longer time to relapse, while relapse rates, endoscopic healing, histological remission and safety were comparable between groups. Although these findings suggest that a longer taper may be advantageous in patients receiving conventional maintenance therapy, several methodological limitations temper their interpretation. Nevertheless, this study provides valuable randomised evidence in an area still largely guided by expert opinion and highlights the need for adequately powered trials that tailor steroid tapering to the maintenance strategy while minimising cumulative corticosteroid exposure.
- Open Access
- 23 June 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8 (3)
“School life in children with inflammatory Bowel Diseases: from a national survey to a patient-driven awareness initiative”
Background: School plays a crucial role in the daily life of pediatric patients with inflammatory bowel disease (IBD). Our study aimed to evaluate patients’ perspectives on school environment and identify improvement areas. Methods: An anonymized patient-driven school survey was distributed via an online platform between February and November 2024 to all pediatric IBD patients and families registered with the Italian IBD patient association (AMICI). Results: Overall, 362 IBD patients responded, of whom 326/362 (90%) were in secondary school. Most respondents reported being aware of their disease (327/342, 96%). While the majority expressed a positive attitude towards school (269/342, 79%) and had disclosed their condition to at least 1 person at school (286/318, 90%), challenges were identified. Only 91/308 (30%) and 84/318 (26%) felt often understood by teachers and peers, respectively. Toilet access was problematic, with 225/318 (71%) expressing fear of using school bathrooms. Additionally, 80/313 (26%) experienced at least occasionally physical/verbal bullying. More than half (172/310, 55%) attended school despite feeling unwell to avoid criticism, with a minority having opportunities to catch up on missed lessons (95/261, 36%). To address these issues, patients’ suggestions were training programs to educate teachers/peers and practical improvements in restroom access and absences management. Conclusions: This national patient-driven survey highlights substantial unmet needs in the school environment for children/young adults with IBD, underscoring the need for targeted interventions to improve inclusion and quality of life. Patient associations play a key role in identifying everyday challenges and fostering collaboration among clinicians, institutions, and policymakers to implement meaningful change.
- 23 June 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8 (3)
Open Access“School life in children with inflammatory Bowel Diseases: from a national survey to a patient-driven awareness initiative”
Background: School plays a crucial role in the daily life of pediatric patients with inflammatory bowel disease (IBD). Our study aimed to evaluate patients’ perspectives on school environment and identify improvement areas. Methods: An anonymized patient-driven school survey was distributed via an online platform between February and November 2024 to all pediatric IBD patients and families registered with the Italian IBD patient association (AMICI). Results: Overall, 362 IBD patients responded, of whom 326/362 (90%) were in secondary school. Most respondents reported being aware of their disease (327/342, 96%). While the majority expressed a positive attitude towards school (269/342, 79%) and had disclosed their condition to at least 1 person at school (286/318, 90%), challenges were identified. Only 91/308 (30%) and 84/318 (26%) felt often understood by teachers and peers, respectively. Toilet access was problematic, with 225/318 (71%) expressing fear of using school bathrooms. Additionally, 80/313 (26%) experienced at least occasionally physical/verbal bullying. More than half (172/310, 55%) attended school despite feeling unwell to avoid criticism, with a minority having opportunities to catch up on missed lessons (95/261, 36%). To address these issues, patients’ suggestions were training programs to educate teachers/peers and practical improvements in restroom access and absences management. Conclusions: This national patient-driven survey highlights substantial unmet needs in the school environment for children/young adults with IBD, underscoring the need for targeted interventions to improve inclusion and quality of life. Patient associations play a key role in identifying everyday challenges and fostering collaboration among clinicians, institutions, and policymakers to implement meaningful change.
- Top Cited PapersOpen Access
- 14 February 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (2) , 318
Diet and Gut Microbiota in Inflammatory Bowel Disease: A Clinical and Nutritional Perspective
Inflammatory bowel diseases, comprising Crohn’s disease and ulcerative colitis, represent chronic inflammatory disorders with rising global incidence, underscoring the pivotal role of modifiable environmental factors in disease pathogenesis. Diet and intestinal microbiota have emerged as critical bidirectional therapeutic targets through complex interactions with host immune responses. Epidemiological evidence demonstrates that healthy and high fiber diets reduce disease risk, while ultra-processed foods and inflammatory dietary patterns increase susceptibility. Therapeutic nutritional interventions, including exclusive enteral nutrition, the Crohn’s Disease Exclusion Diet combined with partial enteral nutrition, and the Mediterranean diet can induce and maintain clinical remission while promoting favorable microbiome modifications characterized by the enrichment of butyrate-producing taxa such as Faecalibacterium prausnitzii and Roseburia species, alongside a reduction in pathogenic Proteobacteria. Micronutrient deficiencies affect up to 78% of patients through malabsorption, chronic blood losses, dietary restrictions, and drug–nutrient interactions. Nutritional status significantly impacts surgical outcomes, with preoperative malnutrition and sarcopenia associated with increased postoperative complications, and it reciprocally influences biologic therapy response. Integration of personalized, microbiome-informed dietary strategies as complementary components of comprehensive treatment plans represents a promising therapeutic frontier, requiring multidisciplinary collaboration, rigorous clinical trials with standardized microbiome analyses, and precision nutrition algorithms accounting for disease phenotype, baseline microbial composition, and individual patient characteristics to optimize outcomes and improve quality of life.
- 14 February 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (2) , 318
Top Cited PapersOpen AccessDiet and Gut Microbiota in Inflammatory Bowel Disease: A Clinical and Nutritional Perspective
Inflammatory bowel diseases, comprising Crohn’s disease and ulcerative colitis, represent chronic inflammatory disorders with rising global incidence, underscoring the pivotal role of modifiable environmental factors in disease pathogenesis. Diet and intestinal microbiota have emerged as critical bidirectional therapeutic targets through complex interactions with host immune responses. Epidemiological evidence demonstrates that healthy and high fiber diets reduce disease risk, while ultra-processed foods and inflammatory dietary patterns increase susceptibility. Therapeutic nutritional interventions, including exclusive enteral nutrition, the Crohn’s Disease Exclusion Diet combined with partial enteral nutrition, and the Mediterranean diet can induce and maintain clinical remission while promoting favorable microbiome modifications characterized by the enrichment of butyrate-producing taxa such as Faecalibacterium prausnitzii and Roseburia species, alongside a reduction in pathogenic Proteobacteria. Micronutrient deficiencies affect up to 78% of patients through malabsorption, chronic blood losses, dietary restrictions, and drug–nutrient interactions. Nutritional status significantly impacts surgical outcomes, with preoperative malnutrition and sarcopenia associated with increased postoperative complications, and it reciprocally influences biologic therapy response. Integration of personalized, microbiome-informed dietary strategies as complementary components of comprehensive treatment plans represents a promising therapeutic frontier, requiring multidisciplinary collaboration, rigorous clinical trials with standardized microbiome analyses, and precision nutrition algorithms accounting for disease phenotype, baseline microbial composition, and individual patient characteristics to optimize outcomes and improve quality of life.
- Open Access
- 10 February 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (4) , 562
“Reply to: Cost evaluation of mass screening of celiac disease in Italy: Prediction is very difficult, especially if it is about the future”
- 10 February 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (4) , 562
Open Access“Reply to: Cost evaluation of mass screening of celiac disease in Italy: Prediction is very difficult, especially if it is about the future”
- 28 October 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (12) , 2339-2346
Economic and organizational impact of a paediatric mass screening program for coeliac disease in Italy
- 28 October 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (12) , 2339-2346
Economic and organizational impact of a paediatric mass screening program for coeliac disease in Italy
- 24 July 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (4) , 1122-1123
Letter to Editor: Approach to anaemia in gastrointestinal disease: A position paper by the ESPGHAN Gastroenterology Committee
- 24 July 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (4) , 1122-1123
Letter to Editor: Approach to anaemia in gastrointestinal disease: A position paper by the ESPGHAN Gastroenterology Committee
- Open Access
- 18 July 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (3) , 765-815
Management of paediatric ulcerative colitis, part 1: Ambulatory care—An updated evidence‐based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation
Objectives: Despite advances in the management of ambulatory paediatric ulcerative colitis (UC), challenges remain as many patients are refractory to therapy and some require colectomy. The aim of these guidelines is to provide an update on optimal care for UC through detailed recommendations and practice points. Methods: These guidelines are an update to those published in 2018 and are a joint effort of the Paediatric IBD Porto group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation. An extensive literature search with subsequent evidence appraisal using the Oxford methodology was performed, followed by three online voting sessions and a consensus face‐to‐face meeting. Thirty‐nine recommendations and 77 practice points were endorsed by the 25 experts with at least an 84% consensus rate. Results: Robust evidence‐based recommendations and detailed practice points are provided. In addition to reemphasising and updating the role of more ‘traditional’ UC therapies, these guidelines outline optimising the use of antitumour necrosis factor therapies and integrating newer biologics and small molecules, as well as supportive therapy, to improve outcomes and provide an updated management algorithm. Measurement and monitoring tools and decision aids are provided, and additional aspects, including nutritional support, extraintestinal manifestations, pouchitis, inflammatory bowel disease‐unclassified and patient support, are discussed. Some aspects, including surgery and thromboprophylaxis, are covered in the acute severe UC guidelines. Conclusions: These guidelines serve as an aid in managing children with UC through a combination of evidence‐based recommendations and more practical practice points in the ambulatory setting.
- 18 July 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (3) , 765-815
Open AccessManagement of paediatric ulcerative colitis, part 1: Ambulatory care—An updated evidence‐based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation
Objectives: Despite advances in the management of ambulatory paediatric ulcerative colitis (UC), challenges remain as many patients are refractory to therapy and some require colectomy. The aim of these guidelines is to provide an update on optimal care for UC through detailed recommendations and practice points. Methods: These guidelines are an update to those published in 2018 and are a joint effort of the Paediatric IBD Porto group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation. An extensive literature search with subsequent evidence appraisal using the Oxford methodology was performed, followed by three online voting sessions and a consensus face‐to‐face meeting. Thirty‐nine recommendations and 77 practice points were endorsed by the 25 experts with at least an 84% consensus rate. Results: Robust evidence‐based recommendations and detailed practice points are provided. In addition to reemphasising and updating the role of more ‘traditional’ UC therapies, these guidelines outline optimising the use of antitumour necrosis factor therapies and integrating newer biologics and small molecules, as well as supportive therapy, to improve outcomes and provide an updated management algorithm. Measurement and monitoring tools and decision aids are provided, and additional aspects, including nutritional support, extraintestinal manifestations, pouchitis, inflammatory bowel disease‐unclassified and patient support, are discussed. Some aspects, including surgery and thromboprophylaxis, are covered in the acute severe UC guidelines. Conclusions: These guidelines serve as an aid in managing children with UC through a combination of evidence‐based recommendations and more practical practice points in the ambulatory setting.
- 17 June 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (3) , 816-851
Management of paediatric ulcerative colitis, part 2: Acute severe colitis—An updated evidence‐based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization
Acute severe colitis (ASC) is a relatively frequent manifestation in children with ulcerative colitis and one of the few emergencies in paediatric gastroenterology. A standardized proactive approach based on tight monitoring and timely medical and surgical interventions may improve patients' outcomes. We aimed to update the previous ASC guidelines using detailed recommendations and practice points, based on a systematic review of the literature and consensus of experts. These guidelines update is a joint effort of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization. A systematic search was performed in Pubmed Ovid Medline, Embase and Cochrane databases using 13 predefined PICO (patient, intervention, comparison, outcomes) based questions and 30 non‐PICO based questions. Grading methodology was based on the Oxford Centre for Evidence‐Based Medicine—Levels of evidence. The questions were addressed by working subgroups following an iterative consensus voting process, including three online voting meetings and one face‐to‐face meeting. A total of 36 recommendations and 72 practice points were endorsed with a consensus rate of at least 88% for all statements, regarding initial evaluation, monitoring, medical and surgical treatment of ASC in children. Several topics have been revised since the previous 2018 guidelines and differ from corresponding published adult guidelines. These guidelines present a comprehensive overview of the management of ASC in children, offering practical recommendations and practice points aiming to standardize clinical and surgical treatment and improve outcomes of this severe scenario.
- 17 June 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (3) , 816-851
Management of paediatric ulcerative colitis, part 2: Acute severe colitis—An updated evidence‐based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization
Acute severe colitis (ASC) is a relatively frequent manifestation in children with ulcerative colitis and one of the few emergencies in paediatric gastroenterology. A standardized proactive approach based on tight monitoring and timely medical and surgical interventions may improve patients' outcomes. We aimed to update the previous ASC guidelines using detailed recommendations and practice points, based on a systematic review of the literature and consensus of experts. These guidelines update is a joint effort of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization. A systematic search was performed in Pubmed Ovid Medline, Embase and Cochrane databases using 13 predefined PICO (patient, intervention, comparison, outcomes) based questions and 30 non‐PICO based questions. Grading methodology was based on the Oxford Centre for Evidence‐Based Medicine—Levels of evidence. The questions were addressed by working subgroups following an iterative consensus voting process, including three online voting meetings and one face‐to‐face meeting. A total of 36 recommendations and 72 practice points were endorsed with a consensus rate of at least 88% for all statements, regarding initial evaluation, monitoring, medical and surgical treatment of ASC in children. Several topics have been revised since the previous 2018 guidelines and differ from corresponding published adult guidelines. These guidelines present a comprehensive overview of the management of ASC in children, offering practical recommendations and practice points aiming to standardize clinical and surgical treatment and improve outcomes of this severe scenario.